First human tests begin for new liver disease drug
NCT ID NCT06485245
Summary
This is a very early-stage study to check the safety of a new drug called CS060304, which is being developed for a liver condition called MASH. The study will involve 80 healthy volunteers and people with high cholesterol to see how their bodies handle single and multiple doses of the drug. The main goal is to understand the drug's safety profile and how it moves through the body, not to treat the disease at this point.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
Conditions
Explore the condition pages connected to this study.